☆ 4.7 Review

Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Virology

Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis

Fangyuan Tian et al.

Summary: This study aimed to evaluate the efficacy and safety of nirmatrelvir-ritonavir compared with other antiviral drugs and the impact of different antiviral drugs on the short- and long-term effects of COVID-19. The results showed that nirmatrelvir-ritonavir can reduce the mortality and hospitalization of COVID-19 patients compared with other antiviral drugs, with little difference in safety compared to the control group.

JOURNAL OF MEDICAL VIROLOGY (2023)

添加到收藏夹

Review Infectious Diseases

Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis

Chienhsiu Huang et al.

Summary: The therapeutic impact of molnupiravir in the Omicron variant phase is still uncertain. A meta-analysis of six studies found that molnupiravir reduced the risk of mortality by 34% and the risk of disease progression by 37% in adult COVID-19 patients. It also showed faster reduction in viral loads compared to placebo. However, there was no clinical benefit of reducing all-cause mortality in mild to moderate COVID-19 patients with high COVID-19 vaccination coverage.

ANTIBIOTICS-BASEL (2023)

添加到收藏夹

Review Medicine, Research & Experimental

RdRp inhibitors and COVID-19: Is molnupiravir a good option?

Seyed Mohammad Reza Hashemian et al.

Summary: Rapid changes in the viral genome allow viruses to evade host immune response, RNA-dependent RNA polymerase is crucial in RNA viral infections. Researchers urgently seek effective treatments for COVID-19, with molnupiravir identified as a potential therapeutic agent.

BIOMEDICINE & PHARMACOTHERAPY (2022)

添加到收藏夹

Article Immunology

Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates

Katie R. Mollan et al.

Summary: The presence of SARS-CoV-2-specific antibodies is strongly associated with infectious virus clearance in COVID-19 outpatients. Seropositivity appears to be a more reliable marker of infectious virus clearance than patient-reported COVID-19 symptoms.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Review Infectious Diseases

Effect of sofosbuvir-based treatment on clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials

Chi-Kuei Hsu et al.

Summary: This systematic review and meta-analysis evaluated the efficacy of sofosbuvir-based antiviral treatment for COVID-19. The study found that sofosbuvir-based treatment can reduce mortality, improve clinical recovery rate, and decrease the need for mechanical ventilation and intensive care unit admission in COVID-19 patients. It also showed that sofosbuvir-based treatment is safe. However, further large-scale studies are needed to confirm these findings.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

添加到收藏夹

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Cell Biology

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

William A. Fischer et al.

Summary: In a clinical trial, the safety, tolerability, and antiviral efficacy of molnupiravir were evaluated in unvaccinated individuals with confirmed SARS-CoV-2 infection. The study found that participants receiving high-dose molnupiravir had a shorter time to viral RNA clearance and a lower detection rate of infectious virus. Molnupiravir was well tolerated across all doses.

SCIENCE TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Letter Medicine, General & Internal

Efficacy and safety of molnupiravir for COVID-19 patients

Maurish Fatima et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2022)

添加到收藏夹

News Item Multidisciplinary Sciences

AFRICAN CLINICAL TRIAL DENIED ACCESS TO KEY COVID DRUG

Heidi Ledford et al.

NATURE (2022)

添加到收藏夹

Article Critical Care Medicine

Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study

Lixue Huang et al.

Summary: With the ongoing COVID-19 pandemic, a study was conducted to characterize the longitudinal evolution of health outcomes in hospitalized survivors of COVID-19 over a period of 2 years. The study found that although most survivors recovered and returned to work within 2 years, a significant proportion of them experienced persistent symptoms and health problems. These findings emphasize the need for further research and interventions to understand and reduce the risk of long-term COVID-19.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Critical Care Medicine

Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

Rachael A. Evans et al.

Summary: This study aimed to describe recovery one year after hospital discharge for COVID-19 and identify potential therapeutic targets by analyzing inflammatory profiles. The results showed that a significant proportion of patients did not fully recover one year after discharge. Female sex, obesity, and invasive mechanical ventilation were associated with lower likelihood of full recovery. Inflammation and obesity may be treatable traits that need further investigation in clinical trials.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 A Randomized, Placebo-Controlled Trial

Matthew G. Johnson et al.

Summary: Compared with placebo, molnupiravir has shown additional clinical benefits in the treatment of COVID-19 patients, including faster normalization of inflammatory markers and oxygen saturation, as well as reduced need for respiratory interventions and emergency care visits.

ANNALS OF INTERNAL MEDICINE (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19

Behnam Amani et al.

Summary: This meta-analysis found that three doses of molnupiravir (200, 400, and 800 mg) are safe for COVID-19 patients. Further research is needed to confirm these findings.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

添加到收藏夹

Review Virology

Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials

Fangyuan Tian et al.

Summary: This study systematically reviewed and synthesized the safety and efficacy of COVID-19 vaccines in children and adolescents. The findings showed that most adverse events following immunization were similar between the vaccine and placebo groups, with mild to moderate reactions being common. The investigated mRNA vaccine was found to be highly efficacious in preventing COVID-19 among children and adolescents.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial

Rongrong Zou et al.

Summary: This study evaluated the antiviral efficacy and safety of molnupiravir in patients infected with the SARS-CoV-2 Omicron variant. The results showed that molnupiravir significantly accelerated viral RNA clearance and had a good safety profile.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study

Carlos K H Wong et al.

LANCET (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance

Robert Flisiak et al.

Summary: This study assessed the effectiveness of molnupiravir in hospitalized COVID-19 patients during the Omicron variant dominance, finding a significant reduction in mortality with MOL treatment, particularly in patients over 80 years of age.

PHARMACOLOGICAL REPORTS (2022)

添加到收藏夹

Article Psychology, Biological

Life expectancy changes since COVID-19

Jonas Schoeley et al.

Summary: In 2021, there were diverging impacts of the COVID-19 pandemic on life expectancies in different regions, with vaccination rates negatively correlated with life expectancy deficits. Generally, countries in western Europe saw improvements in life expectancy, while those in eastern Europe and the United States experienced sustained deficits.

NATURE HUMAN BEHAVIOUR (2022)

添加到收藏夹

Article Infectious Diseases

Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent

Ching-Chi Lee et al.

Summary: Molnupiravir, an oral antiviral agent, has shown significant efficacy in treating COVID-19. Clinical trials have demonstrated its potential importance in treating COVID-19 patients and preventing virus transmission.

ANTIBIOTICS-BASEL (2021)

添加到收藏夹

Review Microbiology

Structural biology of SARS-CoV-2 and implications for therapeutic development

Haitao Yang et al.

Summary: The COVID-19 pandemic caused by SARS-CoV-2 has led to an unprecedented global health crisis, with limited therapeutic options available. Understanding the structure and function of the 29 proteins encoded by SARS-CoV-2 is crucial for developing novel therapeutics and treatment interventions. These proteins play various roles in the viral life cycle, from entry into host cells to genome replication and transcription, highlighting their potential as targets for therapeutic interventions.

NATURE REVIEWS MICROBIOLOGY (2021)

添加到收藏夹

Article Virology

Non-Nucleotide RNA-Dependent RNA Polymerase Inhibitor That Blocks SARS-CoV-2 Replication

Milan Dejmek et al.

Summary: The RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 is identified as a prime target for the development of new antivirals. Inhibitors originally discovered for flavivirus RdRp, such as HeE1-2Tyr and related derivatives, have also been found to significantly inhibit SARS-CoV-2 RdRp, as demonstrated through polymerase and cell-based antiviral assays.

VIRUSES-BASEL (2021)

添加到收藏夹

Editorial Material Biotechnology & Applied Microbiology

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Guangdi Li et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

添加到收藏夹

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

添加到收藏夹

Article Mathematical & Computational Biology

A basic introduction to fixed-effect and random-effects models for meta-analysis

Michael Borenstein et al.

RESEARCH SYNTHESIS METHODS (2010)

添加到收藏夹

Review Medicine, General & Internal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

PLOS MEDICINE (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.